Pharma Focus Asia
Eppendorf Bioprocess Solutions

AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets

Friday, October 30, 2020

AbCellera and Kodiak Sciences Inc. announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Following a previously successful collaboration, AbCellera will use its full stack, AI-powered antibody discovery technology to discover and identify a large panel of antibodies against new targets designated by Kodiak.

“Kodiak was one of AbCellera’s very first partners, and we are proud to expand our collaboration to support their innovative team in the fight against retinal diseases that cause blindness,” said Carl Hansen, Ph.D., President and CEO of AbCellera. “We are committed to making state-of-the-art antibody discovery broadly available to partners, empowering them to bring new therapies to patients quickly.”

Kodiak develops disruptive products and platforms to prevent and treat the leading causes of blindness. Kodiak’s ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine.

“In our previous work with AbCellera, they delivered quality therapeutic antibody candidates with unique epitope and bioactivity behaviors that were advanced for clinical development. We have been impressed with the growth and power of their platform, both the biology-driven as well as the software-driven aspects. We are delighted to work with their experienced and dedicated team again,” said Victor Perlroth, M.D., CEO of Kodiak Sciences. “The value AbCellera brings to us as a partner is not only their state-of-the-art technology but also their expertise in working with us to discover superior and diverse therapeutic antibody candidates for novel disease targets.”

AbCellera searches, decodes, and analyzes natural immune responses to identify antibodies for next-generation therapeutics. A modern operating system for antibody discovery, the platform integrates patented and proprietary technologies to advance the identification and development of new antibody therapies.

Under the terms of the agreement, AbCellera will receive research and development payments and is eligible for downstream milestone payments, as well as royalties on net sales. Other financial terms were not disclosed.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACPHI Korea 2023Bora Pharmaceutical - A robust approach to analytical testing is essentialSelangor International Expo MEDIC 2023TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 20233rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 202320th Anniversary Hospitalog Asia 2023
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology